Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Journal: Oncoimmunology
Published: June 16, 2019
Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Journal: International journal of cancer
Published: February 15, 2019
Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 06, 2018
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.
Journal: Cancer immunology research
Published: September 10, 2018
Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.
Journal: Cancer discovery
Published: September 06, 2018
CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.
Journal: EMBO molecular medicine
Published: August 16, 2018
The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.
Journal: Immunology and cell biology
Published: March 06, 2018
Temporal Regulation of Natural Killer T Cell Interferon Gamma Responses by β-Catenin-Dependent and -Independent Wnt Signaling.
Journal: Frontiers in immunology
Published: November 14, 2017
Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis.
Journal: Cancer immunology research
Published: June 29, 2017
Last Updated: 09/26/2026